Abstract
Cysteine proteases are implicated in a variety of human physiological processes and also form an essential component of the life cycle of a number of pathogenic protozoa and viruses. The present review highlights the drug design approaches utilized to understand the mechanism of inhibition and discovery of inhibitors against protozoal cysteine protease, falcipain (a cysteine protease of P. falciparum which causes malaria), and viral cysteine protease, SARS-CoV Mpro (a cysteine protease of severe acute respiratory syndrome corona virus). The article describes rational approaches for the design of inhibitors and focuses on a variety of structure as well as ligand-based modeling strategies adopted for the discovery of the inhibitors. Also, the key features of ligand recognition against these targets are accentuated. Although no apparent similarities exist between viral and protozoal cysteine proteases discussed here, the goal is to provide examples of rational drug design approaches adopted to design inhibitors against these proteases. The current review would be of interest to scientists engaged in the development of drug design strategies to target the cysteine proteases present in mammals and other lower order organisms.
Keywords: Malaria, SARS, cysteine protease, falcipain, SARS 3CLpro or Mpro, knowledge-based drug design
Current Computer-Aided Drug Design
Title: Computational Approaches for the Discovery of Cysteine Protease Inhibitors Against Malaria and SARS
Volume: 6 Issue: 1
Author(s): Falgun Shah, Prasenjit Mukherjee, Prashant Desai and Mitchell Avery
Affiliation:
Keywords: Malaria, SARS, cysteine protease, falcipain, SARS 3CLpro or Mpro, knowledge-based drug design
Abstract: Cysteine proteases are implicated in a variety of human physiological processes and also form an essential component of the life cycle of a number of pathogenic protozoa and viruses. The present review highlights the drug design approaches utilized to understand the mechanism of inhibition and discovery of inhibitors against protozoal cysteine protease, falcipain (a cysteine protease of P. falciparum which causes malaria), and viral cysteine protease, SARS-CoV Mpro (a cysteine protease of severe acute respiratory syndrome corona virus). The article describes rational approaches for the design of inhibitors and focuses on a variety of structure as well as ligand-based modeling strategies adopted for the discovery of the inhibitors. Also, the key features of ligand recognition against these targets are accentuated. Although no apparent similarities exist between viral and protozoal cysteine proteases discussed here, the goal is to provide examples of rational drug design approaches adopted to design inhibitors against these proteases. The current review would be of interest to scientists engaged in the development of drug design strategies to target the cysteine proteases present in mammals and other lower order organisms.
Export Options
About this article
Cite this article as:
Shah Falgun, Mukherjee Prasenjit, Desai Prashant and Avery Mitchell, Computational Approaches for the Discovery of Cysteine Protease Inhibitors Against Malaria and SARS, Current Computer-Aided Drug Design 2010; 6 (1) . https://dx.doi.org/10.2174/157340910790980142
DOI https://dx.doi.org/10.2174/157340910790980142 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry RNA Interference with Chemically Modified siRNA
Current Topics in Medicinal Chemistry Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Semi-synthesis of 1-Deoxypaclitaxel and its Analogues from 1-Deoxybaccatin VI
Medicinal Chemistry Plant Antimicrobial Peptides: An Overview of SuperSAGE Transcriptional Profile and a Functional Review
Current Protein & Peptide Science Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research History, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
Coronaviruses Microwave-Assisted, Solid-Phase Synthesis of a Chiral 1,2,3,4-Tetrahydroquinoline Library
Combinatorial Chemistry & High Throughput Screening Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19
Recent Advances in Inflammation & Allergy Drug Discovery Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Discovery of Small Molecule Fusion Inhibitors Targeting HIV-1 gp41
Current Pharmaceutical Design The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy QSPR in Oral Bioavailability: Specificity or Integrality?
Mini-Reviews in Medicinal Chemistry P1 and P1; Optimization of [3,4]-Bicycloproline P2 Incorporated Tetrapeptidyl α-Ketoamide Based HCV Protease Inhibitors
Letters in Drug Design & Discovery 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors
Current Topics in Medicinal Chemistry Fundamental, Electron Transfer Mechanism by Pyrylium-Type Ions for the Anticancer Drugs 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) and Flavone-8-Acetic Acid (FAA)
Current Medicinal Chemistry - Anti-Cancer Agents Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry